Two Japanese Universities Confirm Depression Drug Paxil Treats Neuropathic Pain
This article was originally published in PharmAsia News
Executive Summary
According to research conducted by psychosomatic medicine professor Kazunori Mine of Fukuoka University, and neuropharmacology professor Kazuhide Inoue of Kyushu University, the depression drug Paxil (paroxetine) was found to treat neuropathic pain, a continuous sharp pain even after direct pain-causing factors have been treated. In 2003, Inoue discovered protein P2×4, which relates to signaling and is found in spinal marrow microglial cells and causes the disease. Paroxetine is believed to constrain the mechanism of action of P2×4. Rats with neuropathic pain symptoms were observed to have drastically reduced pain following administration of Paxil. (Click for more-Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.